GlaxoSmithKline Pakistan (KAR:GLAXO) Other Current Liabilities: ₨5,777 Mil (As of Mar. 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨373.01
GF Value ₨323.95
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Other Current Liabilities?

GlaxoSmithKline Pakistan KAR:GLAXO +0.75% 93 Other Current Liabilities is ₨5,777 Mil as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.95 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pakistan's other current liabilities for the quarter that ended in Mar. 2026 was ₨5,777 Mil.

GlaxoSmithKline Pakistan's quarterly other current liabilities declined from Sep. 2025 (₨9,258 Mil) to Dec. 2025 (₨8,352 Mil) and declined from Dec. 2025 (₨8,352 Mil) to Mar. 2026 (₨5,777 Mil).

GlaxoSmithKline Pakistan's annual other current liabilities increased from Dec. 2023 (₨7,124 Mil) to Dec. 2024 (₨7,903 Mil) and increased from Dec. 2024 (₨7,903 Mil) to Dec. 2025 (₨8,352 Mil).

GlaxoSmithKline Pakistan Other Current Liabilities Related Terms

GlaxoSmithKline Pakistan Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Other Current Liabilities Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,596.73 6,062.13 7,123.77 7,902.66 8,351.60

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,393.20 10,213.11 9,257.71 8,351.60 5,777.20
KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₨5,777 Mil mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Other Current Liabilities of ₨5,777 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on GlaxoSmithKline Pakistan.
Is GlaxoSmithKline Pakistan's Other Current Liabilities too high?
GlaxoSmithKline Pakistan's current Other Current Liabilities is ₨5,777 Mil. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Other Current Liabilities compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Other Current Liabilities of ₨5,777 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on GlaxoSmithKline Pakistan. GlaxoSmithKline Pakistan's current Other Current Liabilities is ₨5,777 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨323.95, compared to a current price of ₨373.01 — trading 15.1% above its estimated fair value. The current Other Current Liabilities is ₨5,777 Mil. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Other Current Liabilities is ₨5,777 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨373.01 is trading 15.1% above its estimated GF Value™ of ₨323.95. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Other Current Liabilities: ₨5,777 Mil
  • GF Value™: ₨323.95 vs. price of ₨373.01 (15.1% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨373.01
Price
₨323.95
GF Value